NeonMind Biosciences Inc (TSE:LCR)
:LCR
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$3.24M
Enterprise ValueC$3.04M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Psilocybin TherapeuticsNeonMind’s explicit focus on psilocybin-based mental health treatments targets an expanding, structural therapeutic area with growing clinical and regulatory interest. A clear therapeutic niche supports durable IP creation and long-term licensing or commercial opportunities if clinical programs advance.
Licensing And Collaboration Revenue ModelA strategy centered on R&D, patents and licensing provides a scalable, lower-capex commercialization path versus building sales infrastructure. Durable partnerships with pharma or health providers can accelerate market access and create recurring royalty streams once assets achieve regulatory approval.
Improving Cash Flow TrajectoryOperating and free cash flows remain negative but show improvement versus the prior year, indicating some progress in cash management or expense control. That trend, combined with moderate absolute debt, can modestly extend runway and reduce near-term financing pressure if sustained.
Bears Say
No Recurring Revenue BaseThe company lacks a stable revenue stream across multiple years, leaving it structurally dependent on milestone payments, collaborations, or capital raises. Without recurring revenue, margin predictability and internal funding capacity are limited, elevating execution and financing risk over months.
Persistent Net LossesSustained operating and net losses, exemplified by a roughly $1.8M 2025 net loss, erode retained capital and increase reliance on external financing. Continued losses constrain reinvestment in R&D and heighten dilution risk for shareholders absent a clear path to revenue generation.
Negative Shareholders' EquityA persistent negative equity position signals structural solvency weaknesses and reduces financial flexibility. It can raise borrowing costs, limit access to traditional credit, and make the company more dependent on dilutive capital raises or non-dilutive partnerships to fund ongoing clinical and operational needs.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$3.24M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 117 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---